Clinical Trial Update: Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates WGI-0301 in combination with nivolumab in patients with hepatocellular carcinoma and renal cell carcinoma. The study status is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• WGI-0301
• nivolumab (nivolumab)

Snippet

Sponsor: Zhejiang Haichang Biotech Co., Ltd. | Conditions: Hepato Cellular Carcinoma (HCC), Renal Cell Cancer | Phase 2 | Status: NOT_YET_RECRUITING